Differences in blood metabolic and molecular biomarkers among normal weight, mildly obese, and moderately obese subjects

Differences in metabolic biomarkers in the blood and gene expression profiles of peripheral blood mononuclear cells among normal weight, mildly obese, and moderately obese subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16654407

Enrollment

Registered

2015-05-07

Start date

2012-06-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood biomarkers of people classified as normal weight, mildly obese and moderately obese according to body mass index (BMI) calculation. Nutritional, Metabolic, Endocrine Obesity

Interventions

Participants are divided into groups according to their BMI: (1) mildly obese subjects (BMI between =25 and <27.5 kg/m2

n = 14), (2) moderately obese subjects (BMI between =27.5 and <30 kg/m2

n = 12) and (3) control group normal weight range (BMI between =18.5 and <23 kg/m2). All participants provide blood samples for screening.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Participants classed as obese, having a BMI of 25~30 kg/m2 and a normal medical history 2. Healthy participants having a BMI 18.5~23 kg/m2

Exclusion criteria

Exclusion criteria: 1. History of cancer or cardiac, renal, hepatic, or infectious disease. 2. Current treatment with insulin 3. Current use of drugs for controlling blood glucose, blood lipids and body weight. 4. History of gastrointestinal surgery 5. Consumption of functional foods or medications that may affect the results of this study

Design outcomes

Primary

Measure	Time frame
1. Leptin, lipids (LDL- and HDL-cholesterol), apolipoprotein B levels and adiponectin 2. Circulating levels of inflammatory cytokines and markers of insulin resistance, oxidative stress, and liver damage.	—

Secondary

Measure	Time frame
1. PBMC transcriptome data 2. Signaling pathways: oxidative phosphorylation; triglyceride synthesis; carbohydrate metabolism; insulin, mTOR, FOXO, RAP1, RAS, and TGF-ß signaling; and ECM–receptor interaction.	—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026